🇺🇸 FDA
Patent

US 12336973

Cancer therapeutic compositions and methods targeting DNAse1L3

granted A61KA61K31/198A61K31/255

Quick answer

US patent 12336973 (Cancer therapeutic compositions and methods targeting DNAse1L3) held by Providence Health & Services—Oregon expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Providence Health & Services—Oregon
Grant date
Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/198, A61K31/255, A61K31/53, A61K31/7105